Integrative Physician's Perspective, With a Special Consideration of St John's Wort
Malignant melanoma is a cancer for which some significant therapeutic advances have occurred in the past decade, but, as Dr Deva Nathan's contribution makes clear, these advances have certainly not solved the problems posed by this dangerous disease. Adjuvant therapy with high-dose interferon-α2b (IFN) has been subjected to several clinical trials, and while improvements have been shown in relapse-free survival time, overall survival does not appear to be improved by this therapy. Furthermore, IFN is plagued with numerous unpleasant side effects. This year's American Society of Clinical Oncology meeting did little to change this situation for stage II patients considering adjuvant therapy. One trial did report better overall survival for stage III patients with a regimen that comprised dacarbazine followed by low-dose interferon therapy. 1 The existence of such an adverse side effect profile with interferon therapy, together with the questionable benefits, make it clear that more is required in the management of melanoma patients. Our other contributors explore what integrative therapies may have to offer in this area.
Dr Michael Uzick has offered an exceptionally thorough review of the literature on natural agents that may be relevant to naturopathic management of melanoma. As he points out, many of the references involve in vitro and in vivo studies, and while it cannot be said that such studies are necessarily directly relevant to treatment or prevention in the patient context, the risk of using agents based on preclinical studies is moderated if they are widely acknowledged to be safe based on other studies. Given that survival rates after a melanoma diagnosis are definitely less than we would like, there is an argument to be made for use of agents that have few drawbacks in terms of toxicity but a potential upside in improving the overall health of a patient and the ability of the body to battle melanoma. Curiously, the use of high-dose interferon, like most conventional antineoplastic drugs, is based on exactly the opposite calculus: it is known to have severe toxic side effects, but its clinical efficacy in prolonging remission has been validated to some extent-at least for those patients who are able to tolerate the adverse side effects.
Another calculus that differs in the conventional and integrative approaches is mentioned specifically by Uzick: the strategy of using several changes together that could have a cumulative effect, although each one alone may not have a significant effect on survival or other important outcomes. This is an approach that I have followed for more than 2 decades, and, with few exceptions, I find it to be generally accurate. This is not to suggest that nonspecific, generic approaches to illness cannot help patients. But when multiple interventions are individualized as a cumulative strategy for the patient, I believe improved outcomes can be seen.
Uzick follows the typical naturopathic approach of investigating possible leads for treatment approaches by following up the epidemiological literature. Thus, he proposes lifestyle interventions based on variables that have established relationships to melanoma occurrence, such as alcohol use, exercise, and toxic metals. The association of melanoma with obesity and low exercise levels is quite interesting. In light of the recent controversy about the relationship of overweight and obesity to survival, 2 it is useful to remember that this discussion has focused on overweight and overall mortality from all causes. 3 No one has yet questioned the relationship between obesity and cancer highlighted in the references cited by Uzick as well as other important recent references in this area. 4 I am not aware of any literature specifying cytotoxic effects or evidence of slowing tumor progression by chelation of arsenic or nickel. Interestingly, though, there have been some in vitro and in vivo observations of antitumor effects of iron-chelating drugs. 5 Iron may play a vital physiological role in the growth and proliferation of cancer cells, 6 so a role for iron-chelating drugs is of potential interest.
Uzick's designation of the multicenter, retrolective cohort study by Augustin et al 7 trial" is somewhat confusing. The retrolective cohort study design is a type of comparative epidemiological cohort study, and as Augustin et al point out, it is recognized as a valid means of evaluating effectiveness of a drug (level II evidence). It is used in the situation in which 2 different treatments for a disease are widely used in clinical practice but large-scale randomized trials comparing the 2 treatments are lacking. Mistletoe has been used widely in Europe, based on individual clinical decisions and the preferences of patients and physicians. Many patients and physicians also elected not to use mistletoe treatment. Mistletoe use thus presents a suitable situation for the retrolective design. In this noninterventional, epidemiological study design, records of nearly 700 patients with stage II or III melanoma were obtained from 35 German and Swiss hospitals known to treat melanoma with and without mistletoe extract. The records were selected without regard to which patients had been treated with mistletoe extract, and data were very carefully extracted for the study.
Once the data had been assembled, the patients who had been treated with mistletoe were separated from those who had not. The latter became a "control" or "watchful waiting" group, who were monitored by their physicians following surgery. Twenty-seven percent of the mistletoe patients and 31% of the control patients were also treated with some kind of adjuvant therapy (eg, chemotherapy, immunotherapy). I am not sure that this constitutes "watchful waiting," but it does at least indicate medical follow-up of all patients. Toxicity and survival outcomes were compared between the 2 groups, using epidemiological statistical models (hazard ratios). At the end of the follow-up period, 8.9% of the mistletoe patients had died versus 10.9% of the control patients.
Uzick correctly recounts the hazard ratios between the 2 groups and accurately presents the contrasts with the randomized controlled trial (RCT) of mistletoe in melanoma. The most significant differences between the retrolective study and the RCT, to my mind, are the higher proportion of stage III melanoma patients in the RCT, the shorter duration of mistletoe treatment in the RCT, and, especially, the differences in mistletoe preparations used. Eighty-three percent of the patients in the retrolective study received the preparation Iscador Pini, which is prepared from mistletoe growing on pine trees and is recommended for melanoma cases by the manufacturer, while the RCT used Iscador Mali, which is prepared from mistletoe growing on apple trees. It is possible, therefore, that mistletoe therapy may be more effective with patients with stage II melanoma, given for a longer period, and using the correct preparation. An RCT that is correctly designed on these principles, derived from the retrolective study, might clarify the one factor that undermines the validity of the observational, retrolective study of Augustin et al-the case-by-case selection of patients to be treated with mistletoe that was exercised by both patient and physician at the participating centers. Being involved in longitudinal studies of patients at my own clinic, I am only too aware of the possibility that patients who self-select to use integrative treatment methods might differ from other patients on variables that are not usually measured clinically. Ultimately, only sensitively and correctly designed randomized trials that are based on appropriately designed preliminary studies will shed light on this question of self-selection. An example of such a preliminary study of mistletoe was published in this journal recently. 8 The herbal approach presented by David Winston, like those of most herbalists practicing with cancer patients today, includes a substantial reliance on diet and strategic use of phytochemicals, in addition to recommending avoidance of some of the proinflammatory and procarcinogenic dietary factors that are associated with melanoma. This makes good sense in the context of administering herbal and other natural treatments: these treatments are typically less aggressive in their activities than conventional medications are (as mentioned above), and eliminating dietary and lifestyle factors that contribute to cancer progression may be critical to enabling such therapies to work. I have, in fact, a strong suspicion that clinical trials of herbal therapies and other natural compounds that are performed in patients eating a standard Western diet may severely underestimate the potentials of these therapies. This is, certainly, something that could be investigated in the context of properly designed trials. I have also wondered if dosages of herbs and natural remedies developed in populations that were of more normal weight than today's American population may be inadequate for contemporary Americans and whether underdosing in overweight and obese patients may be causing null results in current clinical trials. This possibility might be explored in discussions with practicing herbalists, whose input should be considered critical in the design of herbal clinical trials.
Winston presents an herbal therapy that has multiple goals: reducing stress, enhancing immune function, promoting elimination of metabolic wastes, reducing inflammatory prostaglandin production, and preventing metastasis. Multiple herbs for multiple therapeutic goals are typical of traditional herbal practice, as well as of modern integrative medicine. The distrust of "polypharmacy" that many adherents of conventional pharmacology display represents a naïve assessment of the theory behind traditional practice.
Attempts to find or assess "the active compound" in a multicomponent herbal mixture by considering only 1 type of pharmacological activity overlook the essential approach of traditional therapies. These therapies have multiple aims and truly treat the body holistically, addressing the variety of physiological systems that affect a single disease state.
One of the goals in Winston's therapy, enhancing immune function, is quite typical of herbal and many other alternative therapies. Melanoma, like renal cell carcinoma, is one of the few cancers that can actually be treated by an enhancement of immune function, so this goal makes sense from a treatment perspective. However, although it is true that recent research points out that some herbs may aid in functions relevant to immune recognition of cancer cells, maturation of dendritic cells, and stimulation of the Th1 immune system response, it is far from certain that herbs can initiate the type of active immune attack that is needed in the therapy of a potentially aggressive cancer. [9] [10] [11] Thus, my opinion is that Winston's herbal therapy should therefore be viewed as one that is potentially useful as an adjunct to conventional therapy, not as a replacement for it.
One issue raised in Deva Nathan's discussion is the importance of depression as a side effect of interferon treatment. Drug therapy may be considered if moderate to severe depression occurs during interferon therapy. The SSRI drugs fluoextine, paroxetine, and sertraline all have been reported to be useful in IFNinduced depression. Interferon has been observed to be a potent inhibitor of the hepatic isoenzymes of cytochrome P450, CYP1A2, CYP2D6, and CYP2C19. 12 These enzymes are responsible for metabolizing and clearing from the body a large number of prescription drugs. Inhibiting them will reduce clearance and thus increase blood levels of these drugs, which include a number of antidepressant drugs. It is thus advised that if antidepressants are administered during IFN treatment, they should be started at the minimum adult dose to prevent toxic reactions; dosages could be adjusted upward if needed.
Whenever depression is discussed in the integrative treatment context, the question of potential use of St John's wort (SJW) arises. And whenever SJW is discussed in today's medical climate, the topic of drug interactions is unavoidable. Certainly, it is possible that patients under IFN treatment in an integrative clinic may ask about use of SJW. Would use of SJW be sensible for patients undergoing IFN treatment? Is a drug interaction possible, which would decrease blood levels of IFN due to the induction of hepatic cytochromes that SJW is well known to cause (the opposite effect from that of IFN)? On the other hand, in view of the data on IFN and cytochromes just mentioned, would IFN be likely to raise blood levels of SJW, or would it be exempt from such interaction due to being metabolized by some different pathways?
First, it should be noted that SJW has not been evaluated in melanoma patients undergoing treatment with IFN. Only conventional antidepressants have been evaluated in this context. Thus, barring other issues, if a major effect is needed, the conventional agents should be the first choice in this situation. For the patient who might reject treatment with conventional antidepressants or who might be experiencing unacceptable side effects from them, SJW might be considered; however, the question of whether SJW would be effective should the patient be suffering from severe depression ought to be addressed first. An influential trial sponsored by the US National Institutes of Health reported in 2002 that SJW did not appear to be effective with moderate to severe depression, in a trial that also included a sertraline and a placebo group. 13 One difficulty with this trial, however, is that sertraline also showed no difference from the placebo group, a problem that indicates some difficulties in the trial design. A recent publication targets one of the apparent problems with this trial. 14 Blood samples taken from 292 of the 340 patients in this trial were analyzed for the SJW active compound hyperforin (SJW and placebo groups) and sertraline (sertraline group). While sertraline or its metabolites were found in all the sertraline group patients, it was found that 17% of the SJW group had no hyperforin in their plasma, while 17% of the placebo group did have hyperforin in their plasma! This instructive result highlights 2 of the problems with research on SJW and other herbal medicines: problems with quality control (the extract used in the SJW trial was not standardized on content of hyperforin but on hypericin, another, less active antidepressant compound) and the wide availability of biologically active supplements in the community. I have often wondered whether patients assigned to placebo groups might be taking supplements that confused the results of placebo-controlled trials, and this is one of the few instances in which this problem has been confirmed. This "17% solution" of the problem of what happened in the 2002 trial indicates that the use of SJW for moderate to severe depression cannot be ruled out.
Two recent drug equivalence trials conducted in Europe with patients who have moderate or severe depression compared SJW to sertraline and paroxetine. 15, 16 Although drug equivalence trials do suffer from not having a placebo group, both trials found that SJW was equivalent in action to the conventional antidepressants.
The next question to consider in proposing SJW for the IFN-using patient is that of drug interactions.
Would SJW reduce the availability of IFN due to induction of hepatic cytochromes? As it turns out, IFN is not substantially catabolized by the liver. Rather, it is filtered through the kidney, reabsorbed, and degraded in tubular cells. 17 While natural IFN is metabolized to some extent in the liver, recombinant α-2 IFNs, such as the ones used therapeutically, are not. 18 It thus appears that unlike many drugs, IFN is not one that SJW will affect. Will IFN inhibition of cytochrome P450 enzymes, on the other hand, affect SJW? A recent study of hyper forin indicates that the major biotransformation of hyperforin in the liver is conducted by cytochrome P450 isoenzymes CYP450 3A and CYP450 2B. 19 These are not the isoenzymes that are inhibited by IFN. Although it is not considered to be the major antidepressant compound in SJW, hypericin, which does possess some antidepressant activity (as well as a number of other interesting therapeutic potentials), 20 has also been tested for susceptibility to the activities of cytochrome P450 enzymes. 21 In this case, it was observed that administering the CYP450 enzyme inhibitor and inducer cimetidine and carbamazepine to volunteers taking hypericin resulted in no significant differences in hypericin pharmacokinetics, indicating a lack of effect of these enzymes on hypericin. It thus appears that no drug interactions are likely between IFN and SJW, a refreshing result in view of the many recent publications on herb-drug interactions. SJW could thus be a possible antidepressant therapy for IFN-depression patients who do not respond to conventional therapies, who do not want them, or who experience side effects related to the antidepressants. This is quite relevant since SJW appears to have very low rates of adverse events based on either clinical or laboratory assessments. There are, however, no clinical trials that specifically confirm its effectiveness, and it would need to be administered empirically and with close psychiatric monitoring. The finding on renal degradation of IFN does give one pause about the wisdom of administering herbs or other substances that increase elimination through the kidneys, however.
IFN therapy is a prime example of both the need for and the difficulty of integrative approaches to the management of patients receiving conventional therapies. The thyroid, hematological, and liver toxicity due to IFN represents serious physiological concerns. Facile attempts to address these issues integratively, such as the use of liver-protective herbs whose functions are poorly understood, should be foregone in favor of close medical monitoring. This could include dose reductions when appropriate, until more formal experience is gained. Many of the other side effects of chronic IFN administration, including fatigue and anorexia, however, might be addressed with careful, knowledgeable use of supplementation, modifications of lifestyle, and exercise or with strategic dietary counseling. This is certainly an area that deserves further investigation from an integrative medicine viewpoint.
